Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Clinical Research Bill Passed into Law
April 7, 2017
- Ex-Min. Tamura’s Study Group Boots Up with Backing of 17 Healthcare-Related Organizations
April 7, 2017
- Domestic Drug Production Logs 1st Rise in 4 Years: 2015 MHLW Survey
April 6, 2017
- Rare Symposium Planned after Closed-Door Regulatory Head Confab in October
April 6, 2017
- AMED Inks Collaboration Pact with Spanish Authority
April 6, 2017
- “I Don’t Use Biosimilars,” Says Ex-Chief of Japan College of Rheumatology
April 5, 2017
- MHLW Releases “Blue Book” Generic Data List
April 4, 2017
- MHLW Sets Up Office for Startup Support, Starts Receiving Applications for Consultations
April 4, 2017
- MHLW Issues Optimal Use Guidelines for Repatha, Praluent
April 3, 2017
- MHLW to Launch Conditional Early Approval for Medical Devices Too
April 3, 2017
- Cabinet Presents Reform of Drug Discovery Support Network Including Use of CROs, Transfer of Drug Makers’ Employees
April 3, 2017
- Avigan Might Be Used for Pandemic Influenza if Existing NA Inhibitors Are Ineffective: Expert Council
April 3, 2017
- CEFP Kicks Off Discussions on Economic and Fiscal Policy Blueprint for 2017
March 31, 2017
- Members of New Counterfeits Panel Call for Eliminating Cash-and-Carry Dealers
March 31, 2017
- Clinical Research Bill Likely to Clear Diet Early April
March 31, 2017
- MHLW Approves Ninlaro, Intuniv, Other Drugs
March 31, 2017
- MHLW to Set up New Council to Discuss Safety Measures for Pharmacotherapy in the Elderly
March 31, 2017
- Drug Price Survey Sheets to Be Distributed with No Prefectural Govts In-Between: Chuikyo
March 30, 2017
- AMED Racks Up 1st Out-Licensing Cases in Drug Discovery Support Initiative
March 30, 2017
- Chuikyo Gives Ex-Post Nod to Opdivo’s Optimal Use Guidelines for Head-and-Neck Cancer
March 30, 2017
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…